Tianhua Li
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Tianhua Li has a total of 73 co-authors. Here are the top co-authors by number of shared publications:
- Liqun Jiao
Department of Neurosurgery, Xuanwu Hospital, Capital Medical University, Beijing, China
6 shared publications - Tao Wang
Department of Neurosurgery, Xuanwu Hospital, Capital Medical University, Beijing, China
6 shared publications Xiao Zhang
Department of Neurosurgery, Xuanwu Hospital Capital Medical University, Beijing, China
3 shared publications- Adam Andrew Dmytriw
Nuffield Department of Surgical Sciences, Medical Sciences Division, University of Oxford, Oxford, United Kingdom
2 shared publications Colin P Derdeyn
Department of Radiology and Medical Imaging, University of Virginia, Charlottesville, Virginia, USA
2 shared publicationsDelin Liu
Department of Neurosurgery, Xuanwu Hospital, Capital Medical University, Beijing, China (T.W., Y.Y., D.L., J.W., J.L., R.Y., T.L., H.G., X.S., Y.M., L.J.).
2 shared publications
Latest Publications
- Open Access
- 18 March 2026
- Published by Wolters Kluwer Health in International Journal of Surgery
- Vol. 112 (5) , 11170-11177
Association between nonalcoholic fatty liver disease and stroke: a cross-sectional study
Background: Emerging evidence suggests a potential association between nonalcoholic fatty liver disease (NAFLD) and stroke risk, but data from US outpatient populations remain inconclusive. This study aimed to evaluate this association in a nationally representative adult cohort. Methods: A cross-sectional analysis was conducted using data from the National Health and Nutrition Examination Survey (NHANES) cycles 1999–2020. NAFLD was defined by the United States Fatty Liver Index (≥30). Stroke history was self-reported. Multivariable logistic regression models adjusted for sociodemographic factors, metabolic syndrome, and survey weights. Subgroup and sensitivity analyses were performed to assess robustness. Results: Among 13 422 participants (mean age 47.141 years; 50.948% female), 40.426% had NAFLD. Stroke prevalence was significantly higher in the NAFLD group (4.087 vs. 2.215%, P < 0.001). NAFLD was independently associated with stroke in unadjusted (OR 1.804, 95% CI 1.508–2.157, P < 0.001) and demographically adjusted models (OR 1.420, 95% CI 1.171–1.721, P < 0.001). In Model 3, after adjusting for metabolic syndrome, the association was not statistically significant (OR 1.193, 95% CI 0.958–1.485, P = 0.116). In the subgroup analysis, the association between the two diseases was significant in participants aged 50–65 years (OR 1.654, 95% CI 1.044–2.622) and those without hypertension (OR 2.077, 95% CI 1.211–3.328). The connection remained significant in models applying inverse probability weighting (OR 1.611, 95% CI 1.400–1.853, P < 0.001) and continued to exist after non-Hispanic Black participants were excluded (OR 1.290, 95% CI 1.006–1.656, P = 0.045). Conclusions: This study reveals a significant association between NAFLD and stroke, especially in adults aged 50–65 and those without hypertension. These findings suggest that NAFLD is associated with vascular risk; further prospective research is needed to determine whether it should be incorporated into cardiovascular risk assessments. Longitudinal research is needed to confirm whether treating NAFLD reduces stroke incidence.
- 18 March 2026
- Published by Wolters Kluwer Health in International Journal of Surgery
- Vol. 112 (5) , 11170-11177
Open AccessAssociation between nonalcoholic fatty liver disease and stroke: a cross-sectional study
Background: Emerging evidence suggests a potential association between nonalcoholic fatty liver disease (NAFLD) and stroke risk, but data from US outpatient populations remain inconclusive. This study aimed to evaluate this association in a nationally representative adult cohort. Methods: A cross-sectional analysis was conducted using data from the National Health and Nutrition Examination Survey (NHANES) cycles 1999–2020. NAFLD was defined by the United States Fatty Liver Index (≥30). Stroke history was self-reported. Multivariable logistic regression models adjusted for sociodemographic factors, metabolic syndrome, and survey weights. Subgroup and sensitivity analyses were performed to assess robustness. Results: Among 13 422 participants (mean age 47.141 years; 50.948% female), 40.426% had NAFLD. Stroke prevalence was significantly higher in the NAFLD group (4.087 vs. 2.215%, P < 0.001). NAFLD was independently associated with stroke in unadjusted (OR 1.804, 95% CI 1.508–2.157, P < 0.001) and demographically adjusted models (OR 1.420, 95% CI 1.171–1.721, P < 0.001). In Model 3, after adjusting for metabolic syndrome, the association was not statistically significant (OR 1.193, 95% CI 0.958–1.485, P = 0.116). In the subgroup analysis, the association between the two diseases was significant in participants aged 50–65 years (OR 1.654, 95% CI 1.044–2.622) and those without hypertension (OR 2.077, 95% CI 1.211–3.328). The connection remained significant in models applying inverse probability weighting (OR 1.611, 95% CI 1.400–1.853, P < 0.001) and continued to exist after non-Hispanic Black participants were excluded (OR 1.290, 95% CI 1.006–1.656, P = 0.045). Conclusions: This study reveals a significant association between NAFLD and stroke, especially in adults aged 50–65 and those without hypertension. These findings suggest that NAFLD is associated with vascular risk; further prospective research is needed to determine whether it should be incorporated into cardiovascular risk assessments. Longitudinal research is needed to confirm whether treating NAFLD reduces stroke incidence.
- 1 September 2025
- Published by Wolters Kluwer Health in Stroke
- Vol. 56 (9) , 2579-2587
CT Perfusion for Predicting Ischemic Stroke in Patients With Symptomatic Carotid or Middle Cerebral Artery Occlusion: A Post Hoc Analysis of the CMOSS Study
BACKGROUND: It is unknown whether computed tomographic perfusion (CTP) parameters predict ischemic stroke in patients with symptomatic chronic carotid or middle cerebral artery occlusion. METHODS: A post hoc analysis of medically treated patients enrolled in the CMOSS trial (Carotid or Middle Cerebral Artery Occlusion Surgery Study; URL: https://www.clinicaltrials.gov ; Unique identifier: NCT01758614), a randomized controlled trial conducted at 13 centers in China between June 2013 and March 2018. It aimed to compare extracranial-intracranial bypass surgery to medical therapy in patients with symptomatic carotid or middle cerebral artery occlusion and hemodynamic insufficiency. CTP-derived mean transit time and relative cerebral blood flow were collected. The primary outcome was defined as ischemic stroke in the territory of the qualifying artery within 2 years after randomization. The predictive value of CTP for the primary outcome was analyzed by a Cox regression model. Receiver operating characteristic curves were used to calculate optimal cutoff values of CTP parameters. RESULTS: All 165 per-protocol patients (median age=53.7 years, 81.2% men) treated with medical treatment alone were analyzed. Sixteen (9.7%) patients suffered the primary outcome during the 2-year follow-up. Cutoff values of mean transit time >6.5 seconds (symptomatic side) and relative cerebral blood flow ≤0.5 were associated with recurrent stroke. In multivariate Cox regression, mean transit time (adjusted hazard ratio, 3.50 [95% CI, 1.19–10.30]; P =0.02) and relative cerebral blood flow (adjusted hazard ratio, 7.36 [95% CI, 2.27–23.85]; P =0.001) were independently associated with the primary outcome. CONCLUSIONS: CTP-based hemodynamic parameters are predictive of recurrent ischemic stroke in symptomatic patients with chronic carotid or middle cerebral artery occlusion. CTP could be used in patient selection for stratified secondary prevention of stroke in future studies. REGISTRATION: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT01758614.
- 1 September 2025
- Published by Wolters Kluwer Health in Stroke
- Vol. 56 (9) , 2579-2587
CT Perfusion for Predicting Ischemic Stroke in Patients With Symptomatic Carotid or Middle Cerebral Artery Occlusion: A Post Hoc Analysis of the CMOSS Study
BACKGROUND: It is unknown whether computed tomographic perfusion (CTP) parameters predict ischemic stroke in patients with symptomatic chronic carotid or middle cerebral artery occlusion. METHODS: A post hoc analysis of medically treated patients enrolled in the CMOSS trial (Carotid or Middle Cerebral Artery Occlusion Surgery Study; URL: https://www.clinicaltrials.gov ; Unique identifier: NCT01758614), a randomized controlled trial conducted at 13 centers in China between June 2013 and March 2018. It aimed to compare extracranial-intracranial bypass surgery to medical therapy in patients with symptomatic carotid or middle cerebral artery occlusion and hemodynamic insufficiency. CTP-derived mean transit time and relative cerebral blood flow were collected. The primary outcome was defined as ischemic stroke in the territory of the qualifying artery within 2 years after randomization. The predictive value of CTP for the primary outcome was analyzed by a Cox regression model. Receiver operating characteristic curves were used to calculate optimal cutoff values of CTP parameters. RESULTS: All 165 per-protocol patients (median age=53.7 years, 81.2% men) treated with medical treatment alone were analyzed. Sixteen (9.7%) patients suffered the primary outcome during the 2-year follow-up. Cutoff values of mean transit time >6.5 seconds (symptomatic side) and relative cerebral blood flow ≤0.5 were associated with recurrent stroke. In multivariate Cox regression, mean transit time (adjusted hazard ratio, 3.50 [95% CI, 1.19–10.30]; P =0.02) and relative cerebral blood flow (adjusted hazard ratio, 7.36 [95% CI, 2.27–23.85]; P =0.001) were independently associated with the primary outcome. CONCLUSIONS: CTP-based hemodynamic parameters are predictive of recurrent ischemic stroke in symptomatic patients with chronic carotid or middle cerebral artery occlusion. CTP could be used in patient selection for stratified secondary prevention of stroke in future studies. REGISTRATION: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT01758614.
- Open Access
- 24 October 2024
- Published by BMJ in Stroke and Vascular Neurology
- Vol. 10 (4) , 422-430
Stenting for symptomatic intracranial arterial stenosis with different qualifying arteries: a preplanned pooled individual patient data analysis
Background The efficacy of percutaneous transluminal angioplasty and stenting (PTAS) relative to medical management in treating symptomatic intracranial arterial stenosis (ICAS) varies based on the qualifying artery. This study aims to evaluate PTAS compared with medical therapy alone in cases of ICAS involving the internal carotid artery (ICA), middle cerebral artery (MCA), vertebral artery (VA) and basilar artery (BA). Methods This study involves a thorough pooled analysis of individual patient data from two randomised controlled trials, evaluating the efficacy of PTAS in comparison to medical management for symptomatic ICAS with different qualifying arteries. The primary outcome was stroke or death within 30 days postenrolment, or stroke in the region of the qualifying artery beyond 30 days through 1 year. A methodology based on intention-to-treat was employed, and HR accompanied by 95% CIs were used to convey risk estimates. Results The data of 809 individuals were collected from Stenting vs Aggressive Medical Management for Preventing Recurrent Stroke in Intracranial Stenosis trial and China Angioplasty and Stenting for Symptomatic Intracranial Severe Stenosis trial. Four hundred were designated for PTAS, while 409 were assigned to medical therapy alone. For the primary outcome, patients with symptomatic BA stenosis had a significantly higher risk of receiving PTAS compared with medical therapy (17.17% vs 7.77%; 9.40; HR, 2.38 (1.03 to 5.52); p=0.04). However, PTAS had no significant difference in patients with symptomatic ICA (26.67% vs 16.67%; HR, 1.68 (0.78 to 3.62); p=0.19), MCA (8.28% vs 9.79%; HR, 0.85 (0.42 to 1.74); p=0.66) and VA stenosis (9.52% vs 10.71%; HR, 0.91 (0.32 to 2.62); p=0.86) compared with medical therapy. Conclusions PTAS significantly increases the risk of both short-term and long-term stroke in patients with symptomatic BA stenosis. Without significant technological advancements to mitigate these risks, PTAS offers limited benefits. For symptomatic ICA, MCA and VA stenosis, PTAS provided no significant advantage.
- 24 October 2024
- Published by BMJ in Stroke and Vascular Neurology
- Vol. 10 (4) , 422-430
Open AccessStenting for symptomatic intracranial arterial stenosis with different qualifying arteries: a preplanned pooled individual patient data analysis
Background The efficacy of percutaneous transluminal angioplasty and stenting (PTAS) relative to medical management in treating symptomatic intracranial arterial stenosis (ICAS) varies based on the qualifying artery. This study aims to evaluate PTAS compared with medical therapy alone in cases of ICAS involving the internal carotid artery (ICA), middle cerebral artery (MCA), vertebral artery (VA) and basilar artery (BA). Methods This study involves a thorough pooled analysis of individual patient data from two randomised controlled trials, evaluating the efficacy of PTAS in comparison to medical management for symptomatic ICAS with different qualifying arteries. The primary outcome was stroke or death within 30 days postenrolment, or stroke in the region of the qualifying artery beyond 30 days through 1 year. A methodology based on intention-to-treat was employed, and HR accompanied by 95% CIs were used to convey risk estimates. Results The data of 809 individuals were collected from Stenting vs Aggressive Medical Management for Preventing Recurrent Stroke in Intracranial Stenosis trial and China Angioplasty and Stenting for Symptomatic Intracranial Severe Stenosis trial. Four hundred were designated for PTAS, while 409 were assigned to medical therapy alone. For the primary outcome, patients with symptomatic BA stenosis had a significantly higher risk of receiving PTAS compared with medical therapy (17.17% vs 7.77%; 9.40; HR, 2.38 (1.03 to 5.52); p=0.04). However, PTAS had no significant difference in patients with symptomatic ICA (26.67% vs 16.67%; HR, 1.68 (0.78 to 3.62); p=0.19), MCA (8.28% vs 9.79%; HR, 0.85 (0.42 to 1.74); p=0.66) and VA stenosis (9.52% vs 10.71%; HR, 0.91 (0.32 to 2.62); p=0.86) compared with medical therapy. Conclusions PTAS significantly increases the risk of both short-term and long-term stroke in patients with symptomatic BA stenosis. Without significant technological advancements to mitigate these risks, PTAS offers limited benefits. For symptomatic ICA, MCA and VA stenosis, PTAS provided no significant advantage.
- 20 August 2024
- Published by BMJ in Journal of NeuroInterventional Surgery
- Vol. 17 (10) , 1045-1050
Prevalence of intracerebral thrombus detected by optical coherence tomography in patients with posterior circulation stroke or transient ischemic attack
Background: The incidence of thrombosis in patients with intracranial atherosclerotic stenosis (ICAS) remains unclear. Optical coherence tomography (OCT) has the potential to explore the vessel wall structure of posterior-circulation ICAS because of its relatively straight anatomical structure compared with that of the anterior cerebral arteries. This study aimed to determine the prevalence and characteristics of thrombosis in the posterior-circulation ICAS using OCT. Methods: This prospective study was conducted on 135 patients with posterior-circulation arterial stenosis who underwent OCT. All patients were symptomatic and had a severely stenotic lesion (70–99%) in the vetebrobasilar artery. The enrolled patients were classified according to the presence of in situ thrombus as defined by OCT. Clinical data and OCT characteristics were compared. Results: Eighty-two patients diagnosed with posterior-circulation ICAS were enrolled. In situ thrombi were identified in 34 patients. Clinically, patients with in situ thrombus were more prone to cerebral infarctions than transient ischemic attacks. The percentage area of stenosis in the non-thrombus group was significantly lower than that in the thrombus group. The thrombus burden, mean flow area, mean thrombus area, maximum lipid arc, and mean lumen area were significantly different among white, red, and mixed thrombi. Conclusions: We achieved in vivo vessel wall structural analysis of posterior-circulation ICAS with the largest sample size. We also revealed the true incidence of in situ thrombosis and potential corresponding clinical events of posterior-circulation ICAS for the first time.
- 20 August 2024
- Published by BMJ in Journal of NeuroInterventional Surgery
- Vol. 17 (10) , 1045-1050
Prevalence of intracerebral thrombus detected by optical coherence tomography in patients with posterior circulation stroke or transient ischemic attack
Background: The incidence of thrombosis in patients with intracranial atherosclerotic stenosis (ICAS) remains unclear. Optical coherence tomography (OCT) has the potential to explore the vessel wall structure of posterior-circulation ICAS because of its relatively straight anatomical structure compared with that of the anterior cerebral arteries. This study aimed to determine the prevalence and characteristics of thrombosis in the posterior-circulation ICAS using OCT. Methods: This prospective study was conducted on 135 patients with posterior-circulation arterial stenosis who underwent OCT. All patients were symptomatic and had a severely stenotic lesion (70–99%) in the vetebrobasilar artery. The enrolled patients were classified according to the presence of in situ thrombus as defined by OCT. Clinical data and OCT characteristics were compared. Results: Eighty-two patients diagnosed with posterior-circulation ICAS were enrolled. In situ thrombi were identified in 34 patients. Clinically, patients with in situ thrombus were more prone to cerebral infarctions than transient ischemic attacks. The percentage area of stenosis in the non-thrombus group was significantly lower than that in the thrombus group. The thrombus burden, mean flow area, mean thrombus area, maximum lipid arc, and mean lumen area were significantly different among white, red, and mixed thrombi. Conclusions: We achieved in vivo vessel wall structural analysis of posterior-circulation ICAS with the largest sample size. We also revealed the true incidence of in situ thrombosis and potential corresponding clinical events of posterior-circulation ICAS for the first time.
- 15 August 2024
- Published by BMJ in Journal of NeuroInterventional Surgery
Stenting versus medical treatment alone for symptomatic intracranial artery stenosis: a preplanned pooled individual patient data analysis
Background Whether the safety and efficacy of percutaneous transluminal angioplasty and stenting (PTAS) is significantly different from that of medical treatment alone for symptomatic intracranial arterial stenosis (ICAS) is debatable. A study was undertaken to determine the safety and efficacy of both treatments for symptomatic ICAS. Methods This preplanned pooled individual patient data analysis included 400 participants treated with PTAS and 409 treated with medical treatment alone in two large multicenter randomized clinical trials (SAMMPRIS and CASSISS). Patients were treated with PTAS using a self-expanding stent or medical treatment alone. The primary outcome was stroke or death within 30 days, or ischemic stroke in the territory of the qualifying artery more than 30 days after enrollment. Results Individual data were obtained for 809 patients, 451 from SAMMPRIS and 358 from CASSISS. 400 participants were randomly assigned to the PTAS group and 409 to the medical group. The risk of the primary outcome was not significant between the PTAS and medical groups (17.5% vs 13.2%; HR 1.37 (95% CI 0.96 to 1.95), P=0.08). However, the risk of stroke or death within 30 days was higher in the PTAS group (10.5% vs 4.2%; HR 2.62 (95% CI 1.49 to 4.61), PConclusions PTAS poses an increased risk of short-term stroke/death and therefore is not advised as primary treatment for symptomatic ICAS. A balance exists between stroke risks and revascularization benefits. For patients with asymptomatic ICAS of white ethnicity and those with hyperlipidemia or a history of TIA, a thorough assessment is warranted before considering PTAS. Trial registration ClinicalTrials.gov Identifier: NCT00576693, NCT01763320.
- 15 August 2024
- Published by BMJ in Journal of NeuroInterventional Surgery
Stenting versus medical treatment alone for symptomatic intracranial artery stenosis: a preplanned pooled individual patient data analysis
Background Whether the safety and efficacy of percutaneous transluminal angioplasty and stenting (PTAS) is significantly different from that of medical treatment alone for symptomatic intracranial arterial stenosis (ICAS) is debatable. A study was undertaken to determine the safety and efficacy of both treatments for symptomatic ICAS. Methods This preplanned pooled individual patient data analysis included 400 participants treated with PTAS and 409 treated with medical treatment alone in two large multicenter randomized clinical trials (SAMMPRIS and CASSISS). Patients were treated with PTAS using a self-expanding stent or medical treatment alone. The primary outcome was stroke or death within 30 days, or ischemic stroke in the territory of the qualifying artery more than 30 days after enrollment. Results Individual data were obtained for 809 patients, 451 from SAMMPRIS and 358 from CASSISS. 400 participants were randomly assigned to the PTAS group and 409 to the medical group. The risk of the primary outcome was not significant between the PTAS and medical groups (17.5% vs 13.2%; HR 1.37 (95% CI 0.96 to 1.95), P=0.08). However, the risk of stroke or death within 30 days was higher in the PTAS group (10.5% vs 4.2%; HR 2.62 (95% CI 1.49 to 4.61), PConclusions PTAS poses an increased risk of short-term stroke/death and therefore is not advised as primary treatment for symptomatic ICAS. A balance exists between stroke risks and revascularization benefits. For patients with asymptomatic ICAS of white ethnicity and those with hyperlipidemia or a history of TIA, a thorough assessment is warranted before considering PTAS. Trial registration ClinicalTrials.gov Identifier: NCT00576693, NCT01763320.
- Open Access
- 19 June 2024
- Published by Wolters Kluwer Health in International Journal of Surgery
- Vol. 110 (12) , 7889-7899
Anatomical predispositions for silent cerebral infarction postcarotid artery stenting: a retrospective cohort
Background: Silent cerebral infarction (SCI) that manifests following carotid artery stenting (CAS) has been postulated to correlate with cognitive decline, the onset of dementia, and an increased risk of subsequent cerebrovascular events. This investigation aimed to thoroughly examine the potential anatomical predispositions that are linked to the occurrence of SCI post-CAS, and further develop a predictive nomogram that could accurately forecast the risk of SCI post-CAS. Methods: The present investigation conducted a retrospective examination of datasets from 250 individuals presenting with carotid artery stenosis who had been subjected to CAS within a tertiary healthcare institution from June 2020 to November 2021. Stratified by the procedural date, participants were allocated into a training cohort and a validation cohort. A nomogram was constructed predicated on salient prognostic determinants discerned via a multivariate logistic regression analysis. Results: An aggregate of 184 patients were incorporated into the study, of which 60 (32.6%) manifested SCI, whereas 124 (67.4%) did not. Within the training cohort (n=123), age (OR 1.08, 95% CI: 1.01–1.16; P=0.034), aortic arch type (Type III vs. I: OR 10.79, 95% CI: 2.12–54.81; P=0.005), aortic arch variant (OR 47.71, 95% CI: 6.05–376.09; PP=0.014), and proximal tortuosity index (TI) (OR 1.01, 95% CI: 1.00–1.02; P=0.029) were demarcated as standalone risk predispositions for SCI subsequent to CAS. The concordance index (C-index) for the training cohort's nomogram stood at 0.89 (95% CI: 0.84–0.95). Moreover, the said nomogram exhibited commendable efficacy within the validation cohort (C-index=0.94) as well as the entire participant base (C-index=0.90). Furthermore, the decision curve analysis illustrated the exemplary clinical applicability of the nomogram. Conclusions: The findings of this inquiry underscore that age, aortic arch type, aortic arch variant, CCA ostium lesions, and proximal TI serve as independent determinants linked with SCI post-CAS. The formulated nomogram, predicated on these risk factors, possesses robust prognostic significance, and might serve as a valuable adjunct to inform clinical decision-making.
- 19 June 2024
- Published by Wolters Kluwer Health in International Journal of Surgery
- Vol. 110 (12) , 7889-7899
Open AccessAnatomical predispositions for silent cerebral infarction postcarotid artery stenting: a retrospective cohort
Background: Silent cerebral infarction (SCI) that manifests following carotid artery stenting (CAS) has been postulated to correlate with cognitive decline, the onset of dementia, and an increased risk of subsequent cerebrovascular events. This investigation aimed to thoroughly examine the potential anatomical predispositions that are linked to the occurrence of SCI post-CAS, and further develop a predictive nomogram that could accurately forecast the risk of SCI post-CAS. Methods: The present investigation conducted a retrospective examination of datasets from 250 individuals presenting with carotid artery stenosis who had been subjected to CAS within a tertiary healthcare institution from June 2020 to November 2021. Stratified by the procedural date, participants were allocated into a training cohort and a validation cohort. A nomogram was constructed predicated on salient prognostic determinants discerned via a multivariate logistic regression analysis. Results: An aggregate of 184 patients were incorporated into the study, of which 60 (32.6%) manifested SCI, whereas 124 (67.4%) did not. Within the training cohort (n=123), age (OR 1.08, 95% CI: 1.01–1.16; P=0.034), aortic arch type (Type III vs. I: OR 10.79, 95% CI: 2.12–54.81; P=0.005), aortic arch variant (OR 47.71, 95% CI: 6.05–376.09; PP=0.014), and proximal tortuosity index (TI) (OR 1.01, 95% CI: 1.00–1.02; P=0.029) were demarcated as standalone risk predispositions for SCI subsequent to CAS. The concordance index (C-index) for the training cohort's nomogram stood at 0.89 (95% CI: 0.84–0.95). Moreover, the said nomogram exhibited commendable efficacy within the validation cohort (C-index=0.94) as well as the entire participant base (C-index=0.90). Furthermore, the decision curve analysis illustrated the exemplary clinical applicability of the nomogram. Conclusions: The findings of this inquiry underscore that age, aortic arch type, aortic arch variant, CCA ostium lesions, and proximal TI serve as independent determinants linked with SCI post-CAS. The formulated nomogram, predicated on these risk factors, possesses robust prognostic significance, and might serve as a valuable adjunct to inform clinical decision-making.
- Open Access
- 6 April 2023
- Published by American Society of Neuroradiology (ASNR) in American Journal of Neuroradiology
- Vol. 44 (5) , 530-535
Clinical Relevance of Plaque Distribution for Basilar Artery Stenosis
BACKGROUND AND PURPOSE: There is no clear association between plaque distribution and postoperative complications in patients with basilar artery atherosclerotic stenosis. The aim of this study was to determine whether plaque distribution and postoperative complications after endovascular treatment for basilar artery stenosis are related. MATERIALS AND METHODS: Our study enrolled patients with severe basilar artery stenosis who were scanned with high-resolution MR imaging and followed by DSA before the intervention. According to high-resolution MR imaging, plaques can be classified as ventral, lateral, dorsal, or involved in 2 quadrants. Plaques affecting the proximal, distal, or junctional segments of the basilar artery were classified according to DSA. An experienced independent team assessed ischemic events after the intervention using MR imaging. Further analysis was conducted to determine the relationship between plaque distribution and postoperative complications. RESULTS: A total of 140 eligible patients were included in the study, with a postoperative complication rate of 11.4%. These patients were an average age of 61.9 (SD, 7.7) years. Dorsal wall plaques accounted for 34.3% of all plaques, and plaques distal to the anterior-inferior cerebellar artery accounted for 60.7%. Postoperative complications of endovascular treatment were associated with plaques located at the lateral wall (OR = 4.00; 95% CI, 1.21–13.23; P = .023), junctional segment (OR = 8.75; 95% CI, 1.16–66.22; P = .036), and plaque burden (OR = 1.03; 95% CI, 1.01–1.06; P = .042). CONCLUSIONS: Plaques with a large burden located at the junctional segment and lateral wall of the basilar artery may increase the likelihood of postoperative complications following endovascular therapy. A larger sample size is needed for future studies.
- 6 April 2023
- Published by American Society of Neuroradiology (ASNR) in American Journal of Neuroradiology
- Vol. 44 (5) , 530-535
Open AccessClinical Relevance of Plaque Distribution for Basilar Artery Stenosis
BACKGROUND AND PURPOSE: There is no clear association between plaque distribution and postoperative complications in patients with basilar artery atherosclerotic stenosis. The aim of this study was to determine whether plaque distribution and postoperative complications after endovascular treatment for basilar artery stenosis are related. MATERIALS AND METHODS: Our study enrolled patients with severe basilar artery stenosis who were scanned with high-resolution MR imaging and followed by DSA before the intervention. According to high-resolution MR imaging, plaques can be classified as ventral, lateral, dorsal, or involved in 2 quadrants. Plaques affecting the proximal, distal, or junctional segments of the basilar artery were classified according to DSA. An experienced independent team assessed ischemic events after the intervention using MR imaging. Further analysis was conducted to determine the relationship between plaque distribution and postoperative complications. RESULTS: A total of 140 eligible patients were included in the study, with a postoperative complication rate of 11.4%. These patients were an average age of 61.9 (SD, 7.7) years. Dorsal wall plaques accounted for 34.3% of all plaques, and plaques distal to the anterior-inferior cerebellar artery accounted for 60.7%. Postoperative complications of endovascular treatment were associated with plaques located at the lateral wall (OR = 4.00; 95% CI, 1.21–13.23; P = .023), junctional segment (OR = 8.75; 95% CI, 1.16–66.22; P = .036), and plaque burden (OR = 1.03; 95% CI, 1.01–1.06; P = .042). CONCLUSIONS: Plaques with a large burden located at the junctional segment and lateral wall of the basilar artery may increase the likelihood of postoperative complications following endovascular therapy. A larger sample size is needed for future studies.
- Open Access
- 16 December 2020
- Published by MDPI AG in Preprints.org
Nomogram With a Novel Microenvironment Signature Is Systematically Constructed and Validated to Predict the Survival Rate of Glioma Patients.
Glioma accounts for the highest proportion of primary intracranial malignant tumors. Microenvironment enormously influences the process of glioma progression. Our study is to establish an individualized prognostic nomogram for glioma patients with microenvironment signature. Glioma samples of Chinese Glioma Genome Atlas (CGGA) were grouped by the immune and stromal score based on ESTIMATE algorithm. Microenvironment-related genes (MRGs) in glioma were analyzed by R. To determine the best prognostic correlation genes, univariate and multivariate Cox regression analysis were used to analyze MRGs. Use the selected genes (CHI3L1, SOCS3, SLC47A2, COL3A1, SRPX2 and SERPINA3), we established the prognostic risk score model (microenvironment signature) and validated it. Gene Set Enrichment Analysis (GSEA) showed that the high-risk group was mainly enriched in immune and stromal function KEGG pathways. Finally, the nomogram was constructed and evaluated. The receiver operating characteristic (ROC) curve, Calibration plots and decision curve analysis (DCA) of training and validation set indicated the excellent predictive performance of nomogram. In conclusion, the 6-gene microenvironment signature can not only provide directions for the basic research of glioma, but also can be included as an independent prognostic index in nomogram for individual prediction to guide clinical treatment.
- 16 December 2020
- Published by MDPI AG in Preprints.org
Open AccessNomogram With a Novel Microenvironment Signature Is Systematically Constructed and Validated to Predict the Survival Rate of Glioma Patients.
Glioma accounts for the highest proportion of primary intracranial malignant tumors. Microenvironment enormously influences the process of glioma progression. Our study is to establish an individualized prognostic nomogram for glioma patients with microenvironment signature. Glioma samples of Chinese Glioma Genome Atlas (CGGA) were grouped by the immune and stromal score based on ESTIMATE algorithm. Microenvironment-related genes (MRGs) in glioma were analyzed by R. To determine the best prognostic correlation genes, univariate and multivariate Cox regression analysis were used to analyze MRGs. Use the selected genes (CHI3L1, SOCS3, SLC47A2, COL3A1, SRPX2 and SERPINA3), we established the prognostic risk score model (microenvironment signature) and validated it. Gene Set Enrichment Analysis (GSEA) showed that the high-risk group was mainly enriched in immune and stromal function KEGG pathways. Finally, the nomogram was constructed and evaluated. The receiver operating characteristic (ROC) curve, Calibration plots and decision curve analysis (DCA) of training and validation set indicated the excellent predictive performance of nomogram. In conclusion, the 6-gene microenvironment signature can not only provide directions for the basic research of glioma, but also can be included as an independent prognostic index in nomogram for individual prediction to guide clinical treatment.